Selective Serotonin Reuptake Inhibitors (SSRIs), the most widely used drugs for the treatment of depression, have been reported to reduce bone formation and increase the risk of bone fracture. A new study, published in the Journal of Dental Research, investigates the association between SSRIs and the risk of failures in osseointegrated implants.
For the study, a total of 916 dental implants in 490 patients were used to estimate the risk of failure associated with the use of SSRIs. After three to 67 months of follow-up, 38 dental implants failed and 784 succeeded in the nonusers group while 10 failed and 84 succeeded in the SSRIs-users group.
The researchers concluded that compared with non-users of SSRIs, SSRIs usage was associated with an increased risk of dental implants failure. Small implant diameters, bone augmentation and smoking habits also seemed to be associated with higher risk of implant failure.